Follow-The-Filings

Security · featured owners

ADMA Adma Biologics Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 2 Owners
  • Max 0.5%
  • $37M
  • 1 add

ADMA (Adma Biologics Inc.) is held in 2 featured 13F books as of 2026 Q2. Stanley Druckenmiller - Duquesne Family Office is the largest tracked holder by portfolio weight (0.45%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 0.5% (Stanley Druckenmiller - Duquesne Family Office) · not free-float ownership

  1. Stanley Druckenmiller add 0.45%
  2. Terry Smith 0.10%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Stanley Druckenmiller - Duquesne Family Office 2026 Q2 0.45% Add +80.1% 2,784,110 $23M history
Terry Smith - Fundsmith 2026 Q2 0.10% Hold 1,649,493 $14M history

2 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 14 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01,9.01 Filing Doc
DEFA14A Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 2.02,5.02,9.01 Filing Doc
10-K Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 15 rows shown

Filed Form Detail Links
4 Period Jul 24, 2026 Filing Doc
4 Period Jul 16, 2026 Filing Doc
4 Period May 27, 2026 Filing Doc
4 Period May 12, 2026 Filing Doc
4 Period May 11, 2026 Filing Doc
4 Period Apr 1, 2026 Filing Doc
4 Period Mar 16, 2026 Filing Doc
4 Period Mar 13, 2026 Filing Doc
4 Period Mar 6, 2026 · 2 forms Filing Doc
4 Period Mar 5, 2026 Filing Doc
4 Period Feb 26, 2026 Filing Doc
4 Period Feb 19, 2026 · 3 forms Filing Doc
4 Period Feb 17, 2026 Filing Doc
4 Period Feb 9, 2026 · 8 forms Filing Doc
4 Period Dec 15, 2025 Filing Doc

Updated 11 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $258.22M $426.45M $510.17M
Gross profit $88.94M $219.55M $292.76M
Gross margin * 34.4% 51.5% 57.4%
Net income -$28.24M $197.67M $146.93M
Net margin * -10.9% 46.4% 28.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $257.01M $331.41M $466.51M
Total non-current assets * $72.17M $157.27M $157.73M
Total assets $329.18M $488.68M $624.24M
Total current liabilities $49.81M $55.54M $69.54M
Total non-current liabilities * $144.17M $84.12M $77.38M
Total equity $135.21M $349.02M $477.32M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $8.8M $118.67M $50.4M
Cash from investing -$4.98M -$8.58M -$21.89M
Cash from financing -$38.99M -$58.3M -$44.02M
Net change in cash -$35.17M $51.8M -$15.52M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders